CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE
(NASDAQ: CNTB)
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.
1.520
-
(-%)
Range
- - -
(-%)
Open
-
Previous Close
1.520
Bid Price
1.140
Bid Volume
8
Ask Price
1.240
Ask Volume
8
Volume
19,076
Value
-
Remark
View All Events
Loading Chart...
Please login to view stock data and analysis